Rising interest rates are squeezing household budgets, but UK healthcare demand tends to follow need rather than cheap credit. A Simply Wall St screen highlights three established stocks: NIOX Group, HUTCHMED (China), and AstraZeneca. NIOX Group (AIM:NIOX) sells NIOX VERO devices for diagnosing asthma and COPD. It generates £47.5 million in revenue and has a market cap of £269.4 million. Earnings are up 42.9% year on year, with forecast growth of 28.04% a year. HUTCHMED (AIM:HCM), valued at £1.9 billion, develops targeted cancer drugs, led by Fruquintinib and Savolitinib. It earns about $237 million from marketed oncology products, mostly in China. AstraZeneca, valued at £216.1 billion, earns about $62.4 billion from pharmaceuticals. Management says 12 late-stage programmes each have risk-adjusted peak sales potential above $5 billion.

Big Pharma earnings watch: Sanofi, abbvie, astrazeneca, Pfizer & Novo Nordisk. Nov 6, 2026 Pharmaceutical Companies Top Earnings Estimates While Continuing to Raise Drug Prices This week, Sanofi, AbbVie, AstraZeneca, Pfizer and Novo Nordisk rounded out earnings for the third quarter for Big Pharma. All five companies reported earnings that surpassed Wall Street expectations, continuing a pattern of strong financial performance across the pharmaceutical sector. So far in 2026, these companies have increased prices on more than 100 brand name products combined. These results underscore how brand name drug companies continue to deliver strong financial performance following price increases across their portfolios. Get the full recap of Sanofi, AbbVie, AstraZeneca, Pfizer and Novo Nordisk's third quarter earnings below: * Sanofi reported third quarter earnings that beat Wall Street estimates. * The drugmaker reported net sales of $16.16 billion, ahead of expectations of $14.8 billion. * Sales of the company's blockbuster eczema and asthma treatment Dupixent rose to $6.37 billion. * AbbVie's third quarter earnings exceeded Wall Street expectations. * The company's arthritis drug Skyrizi brought in sales of $5.78 billion, while autoimmune drug Rinvoq generated $2.71 billion. * AbbVie brought in $17.4 billion in third quarter revenue, topping analyst estimates. AstraZeneca * AstraZeneca announced third earnings that surpassed Wall Street analyst expectations. * In the third quarter, the company saw revenue of $16.21 billion. * The drugmaker reported they are on track to achieve the goal of $80 billion annual sales by 2030. * AstraZeneca's oncology revenue increased to $7.77 billion, with breast cancer drug Enhertu sales rising to $969 million, and lung cancer drug Imfinzi sales to around $2 billion. * Pfizer reported third quarter earnings that surpassed Wall Street analysts' estimates. * The Big Pharma company's third quarter sales came in at $16.58 billion, topping analysts' expectations of $15.85 billion. * Sales of blockbuster blood thinner drug Eliquis, shared with Bristol Myers Squibb, rose 25 percent to $2.52 billion. * The company increased full-year sales to $62 billion to $64 billion. Novo Nordisk * Novo Nordisk beat Wall Street analysts' expectations for the third quarter. * The Big Pharma giant's third quarter sales came in at $11.9 billion, up four percent year-on-year. * Novo Nordisk's blockbuster weight loss pill Wegovy brought in sales of $810 million. The companies' strong third quarter earnings come after they all engaged in price hikes across their portfolios earlier this year. * So far this year, Sanofi raised the price of nine prescription drugs, including Dupixent, by five percent. * Throughout 2025, Sanofi hiked prices on 11 prescription drugs. * In 2024, Sanofi increased the price of nine prescription drugs, including blockbuster drug Dupixent, by six percent. * Sanofi hiked prices on 20 prescription drugs in 2023. * Sanofi hiked prices on more than 11 prescription drugs in January 2022 - and engaged in an additional round of price hikes that summer. * AbbVie has hiked the price of 21 prescription drugs so far in 2026, including its blockbuster arthritis drug Skyrizi by 4.1 percent. * In 2025, AbbVie hiked prices on 17 prescription drugs, including arthritis treatment Skyrizi by 4.1 percent and autoimmune drug Rinvoq by five percent. * AbbVie increased prices on 18 prescription drugs in 2024, including a 4.5 percent price increase on arthritis drug Skyrizi and a five percent increase on autoimmune treatment Rinvoq. * AbbVie hiked prices on 17 prescription drugs in 2023, including an eight percent increase on blockbuster autoimmune drug Rinvoq. * In 2022, AbbVie increased prices on 14 prescription drugs. AstraZeneca * So far this year, AstraZeneca has increased the price of 19 prescription drugs, including blockbuster immunotherapy medication Imfinzi by 2.7 percent. * AstraZeneca hiked prices on 22 prescription drugs in 2025, including diabetes drug Farxiga by three percent and blood pressure treatment Lokelma by five percent. * AstraZeneca increased prices on 19 prescription drugs in 2024, including oncology drugs Tagrisso and Lynparza by three percent each. * AstraZeneca hiked prices on at least 21 prescription drugs in 2023, including best-selling oncology drugs Tagrisso by three percent and Lynparza by 6.8 percent. * So far in 2026, Pfizer increased the price of 86 prescription drugs by an average of 4.7 percent. * In 2025, Pfizer hiked prices on 86 prescription drugs. * Pfizer hiked prices on more than 88 prescription drugs in 2024. * In 2023, Pfizer hiked drug prices on 92 medications, and in 2022, the company hiked prices on 124 prescriptions in its portfolio. Novo Nordisk * So far in 2026, Novo Nordisk has hiked the price of five prescription drugs. * In 2025, Novo Nordisk increased the cost of 12 prescription drugs at an average rate of 4.7 percent. * Novo Nordisk hiked prices on five prescription drugs in 2024, including a 3.5 percent increase on their blockbuster weight loss drug Ozempic. * In 2023, Novo Nordisk hiked prices on 11 prescription drugs, including a 4.9 percent increase on their GLP-1 drug Ozempic. Read more on third quarter earnings from Gilead, Eli Lilly, Bristol Myers Squibb and Merck HERE. Read more on third quarter earnings from Novartis and GSK HERE. Read more on third quarter earnings from Roche HERE. Read more on third quarter earnings from Johnson & Johnson HERE.

Boston life sciences: october 2026 industry recap. October brought several notable developments across Greater Boston's life sciences and biotechnology sector, highlighting continued investment in research, innovation, and advanced manufacturing. * AstraZeneca opened its $1 billion R&D center in Cambridge's Kendall Square, expanding the region's research capabilities. * Terrestrial Bio opened a new Boston headquarters and manufacturing facility, supporting the development of innovative drug delivery technologies. * Arboretum LifeSciences launched with $30 million in financing to advance genetic testing and precision medicine. * Bambusa Therapeutics raised approximately $169 million through its IPO, reflecting continued investor interest in emerging biotechnology companies. These developments demonstrate the strength of Greater Boston's life sciences ecosystem, even as the industry continues to navigate a changing funding and hiring environment. As organizations invest in research, clinical development, and manufacturing, access to specialized talent remains an important part of supporting long-term growth. At Biomedical Search Consultants, we partner with life sciences organizations to identify and secure talent across research and development, quality assurance, regulatory affairs, clinical operations, and manufacturing. Looking to strengthen your team as you plan for 2027? Connect with Tracy Mason to discuss your hiring needs. Tracy Mason | Division Director Biomedical Search Consultants Phone: (781) 890-8824 Email: [email protected]